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Endogenously produced nitric oxide (NO) has been
shown to play a permissive role in angiogenesis. Although
soluble guanylyl cyclase (sGC) and cGMP generation reg-
ulate many of the vascular actions of NO, the role of
cGMP in new blood vessel formation has not been studied
in detail. Using pharmacological inhibitors and gene-
transfer approaches we have investigated the role of sGC
in angiogenesis and angiogenesis-related properties of
endothelial cells (EC). Initially, we used the chicken cho-
rioallantoic membrane (CAM) as an in vivo model of ang-
iogenesis. We found that sGC is present and enzymatically
active in CAM during the days of maximal angiogenesis.
Inhibition of endogenous sGC in the CAM by ODQ
inhibited neovascularization, whereas exposure to the
NO-independent/heme-dependent activator of sGC, BAY
41–2272 promoted neovessel formation. Similarly, PDE-
5-mediated inhibition of cGMP breakdown by either
sildenafil or zaprinast resulted in increased angiogenesis.
Using zebrafish as a model of vascular development, we
observed that sGC inhibition led to an abnormal ang-
iogenic response in certain vascular beds. In vitro,
increased levels of cGMP due to either (a) pharmacologi-
cal activation of sGC, (b) adenovirus-mediated sGC gene
transfer or (c) PDE-5 inhibition, increased EC prolifera-
tion, migration and assembly into tube-like structure for-
mations. In addition, inhibition of sGC blocked capillary
morphogenesis on matrigel. Moreover, we observed that
sGC mediates the migratory action of vascular EC growth
factor. In order to study the signaling pathways implicated
in cGMP-stimulated angiogenesis, we determined the
phosphorylation status of mitogen-activated protein
kinase (MAPK) members after sGC activation/overexpres-
sion. Adenoviral-mediated over-expression of sGC in EC
increased both extracellular signal-regulated kinase 1/2
(ERK1/2) and p38 MAPK in an ODQ-sensitive manner,
suggesting that these mitogen-activated protein kinases
are downstream effectors of sGC in EC. Moreover, inhibi-
tion of p38 attenuated the cGMP-stimulated EC mobiliza-
tion, while inhibition of MEK1/2 blocked cGMP-induced
cell growth. We conclude that increased levels of intracel-
lular cGMP promote neovascularization, and that sGC
activators and PDE-5 inhibitors are new classes of agents
that could be used to modulate neovessel formation.
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